Assenagon Asset Management S.A. raised its position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) by 210.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 101,544 shares of the biopharmaceutical company’s stock after purchasing an additional 68,844 shares during the […]
Several brokerages have updated their recommendations and price targets on shares of Cara Therapeutics (NASDAQ: CARA) in the last few weeks: 3/16/2023 – Cara Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 3/7/2023 – Cara Therapeutics was downgraded by analysts at Bank of America Co. from a […]
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $10.11 and traded as low as $4.85. Cara Therapeutics shares last traded at $4.92, with a volume of 486,751 shares. Analyst Ratings Changes Several […]
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov. .